文献速递细菌感染、耐药与抗菌药物

2014-16年希腊抗生素耐药性调查(SOAR)结果

Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Greece.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

该研究测定了2014-16年希腊社区获得性呼吸道感染患者分离的99株肺炎链球菌和52株流感嗜血杆菌的药敏。结果显示肺炎链球菌对大环内酯类耐药率高,流感嗜血杆菌对克拉霉素活性降低,作者认为此类药物不宜作为希腊社区获得性肺炎的单药治疗;阿莫西林/克拉维酸保持良好体外活性。

要点

  • 肺炎链球菌对青霉素敏感率按CLSI口服/EUCAST标准为36.4%,按CLSI静脉标准为88.9%。
  • 肺炎链球菌对大环内酯类敏感率仅49.5%(CLSI),对头孢克洛为50.5%。
  • 流感嗜血杆菌中15.4%为β-内酰胺酶阳性,对阿莫西林/克拉维酸、头孢曲松、头孢呋辛和氟喹诺酮类敏感率>95%(CLSI)。

核心结论

  • 由于肺炎链球菌中大环内酯类耐药率高及克拉霉素对流感嗜血杆菌活性降低,这些药物似乎不适合作为希腊社区获得性肺炎的单药治疗。
  • 阿莫西林/克拉维酸保持了极好的体外活性,且与同样有效的氟喹诺酮类不同,在儿科患者中使用是安全的。

研究设计与样本

  • 研究收集2014-16年希腊社区获得性呼吸道感染患者的肺炎链球菌和流感嗜血杆菌分离株,共99株肺炎链球菌和52株流感嗜血杆菌。
  • 采用CLSI肉汤微量稀释法测定MIC,并使用CLSI、EUCAST和药代动力学/药效学(PK/PD)折点评估敏感性。

主要发现

  • 肺炎链球菌:按CLSI口服/EUCAST标准36.4%对青霉素敏感,按CLSI静脉标准88.9%敏感;所有菌株对氟喹诺酮类敏感,≥94%菌株对阿莫西林、阿莫西林/克拉维酸和头孢曲松敏感(CLSI和PK/PD折点)。
  • 肺炎链球菌对甲氧苄啶/磺胺甲噁唑、头孢呋辛、头孢克洛和大环内酯类的敏感率分别为83.8%、69.7%、50.5%和49.5%(CLSI)。
  • 流感嗜血杆菌:15.4%的菌株为β-内酰胺酶阳性;按CLSI标准,对阿莫西林/克拉维酸、头孢曲松、头孢呋辛和氟喹诺酮类的敏感率>95%。
  • 流感嗜血杆菌:按CLSI折点,94.2%对阿奇霉素敏感,但克拉霉素敏感率较低(61.5%);按PK/PD和EUCAST标准,对这两种大环内酯类的敏感率均<5%;对甲氧苄啶/磺胺甲噁唑敏感率为71.2%。

关键数值与推荐

  • 肺炎链球菌对青霉素敏感率:CLSI口服/EUCAST 36.4%,CLSI静脉 88.9%。
  • 肺炎链球菌对甲氧苄啶/磺胺甲噁唑、头孢呋辛、头孢克洛、大环内酯类的敏感率(CLSI)分别为83.8%、69.7%、50.5%、49.5%。
  • 流感嗜血杆菌β-内酰胺酶阳性率15.4%;对阿莫西林/克拉维酸、头孢曲松、头孢呋辛、氟喹诺酮类敏感率>95%(CLSI)。
  • 流感嗜血杆菌对阿奇霉素敏感率94.2%、克拉霉素61.5%(CLSI);对两种大环内酯类敏感率<5%(PK/PD和EUCAST);对甲氧苄啶/磺胺甲噁唑敏感率71.2%。

临床怎么用

  • 作者认为,由于肺炎链球菌大环内酯类耐药率高及克拉霉素对流感嗜血杆菌活性降低,这些药物似乎不适合作为希腊社区获得性肺炎的单药治疗。
  • 作者指出,阿莫西林/克拉维酸保持了极好的体外活性,且与同样有效的氟喹诺酮类不同,在儿科患者中使用是安全的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine antimicrobial susceptibility in isolates of Streptococcus pneumoniae and Haemophilus influenzae collected in 2014-16 from patients with community-acquired respiratory tract infections in Greece. METHODS: MICs were determined by CLSI broth microdilution and susceptibility assessed using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: A total of 99 S. pneumoniae and 52 H. influenzae isolates were collected. Overall, 36.4% of S. pneumoniae were penicillin susceptible by CLSI oral/EUCAST and 88.9% by CLSI intravenous (iv) breakpoints. All were fluoroquinolone susceptible with ≥94% of isolates also susceptible to amoxicillin, amoxicillin/clavulanic acid and ceftriaxone by CLSI and PK/PD breakpoints. Trimethoprim/sulfamethoxazole, cefuroxime, cefaclor and macrolides were less active, with rates of susceptibility of 83.8%, 69.7%, 50.5% and 49.5%, respectively, by CLSI. Generally susceptibility was the same or slightly lower by EUCAST, but the cefaclor difference was much greater. Among H. influenzae, 15.4% of isolates were β-lactamase positive. Susceptibility to amoxicillin/clavulanic acid, ceftriaxone, cefuroxime and the fluoroquinolones was seen in >95% of isolates by CLSI criteria. Susceptibility to azithromycin was seen in 94.2% of isolates using CLSI breakpoints, but clarithromycin susceptibility was lower (61.5%). However, susceptibility to both macrolides was seen in <5% of isolates by PK/PD and EUCAST criteria. Susceptibility to trimethoprim/sulfamethoxazole was seen in 71.2% of isolates. CONCLUSIONS: Owing to the high prevalence of macrolide resistance among S. pneumoniae and the reduced activity of clarithromycin against H. influenzae, it appears that these agents are not appropriate as monotherapy for community-acquired pneumonia in Greece. Amoxicillin/clavulanic acid, on the other hand, maintained excellent in vitro activity and, as opposed to the similarly effective fluoroquinolones, is safe to use in paediatric patients.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Torumkuney D, Papaparaskevas J, Morrissey I, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Greece. J Antimicrob Chemother. 2018. PMID: 29659884. doi:10.1093/jac/dky068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。